Work

Phase 2 study of all‐oral ixazomib, cyclophosphamide and low‐dose dexamethasone for relapsed/refractory multiple myeloma

Year: 2018

Type: article

Study design: Clinical Trial

Source: British Journal of Haematology

DOI: 10.1111/bjh.15679

Authors: Shaji K. Kumar, Norbert Grzasko, Sosana Delimpasi, Wieslaw W. Jedrzejczak, Sebastian Grosicki, Marie‐Christine Kyrtsonis, Andrew Spencer, Neeraj Gupta, Zhaoyang Teng, Catriona Byrne, Richard Labotka, Meletios A. Dimopoulos

Institutions: Mayo Clinic, Medical University of Lublin, Lublin Oncology Center, Evangelismos Hospital, Medical University of Warsaw, Medical University of Silesia, Laiko General Hospital of Athens, The Alfred Hospital, Monash University, Takeda Oncology (United States), National and Kapodistrian University of Athens

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Takeda Oncology

OpenAlex ID: W2901369628

FWCI: 1.519

Cites: 32

Cited by: 23

Related to: 10